Difference between revisions of "Tasian SK, et al. Front. Oncol. (2014) cited as Ref 352 in DOI: 10.1038/s41392-020-0110-5 (Q9615)"
Jump to navigation
Jump to search
(Created claim: title (P93): Targeting the PI3K/mTOR pathway in pediatric hematologic malignancies, #quickstatements; #temporary_batch_1590010982689) |
(Created claim: Page(s) (P105): 108-, #quickstatements; #temporary_batch_1590074839150) |
||
| Property / Page(s) | |||
| + | 108- | ||
| Property / Page(s): 108- / rank | |||
| + | Normal rank | ||
Latest revision as of 15:38, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Tasian SK, et al. Front. Oncol. (2014) cited as Ref 352 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Tasian SK
0 references
Teachey DT
0 references
Rheingold SR
0 references
2014
0 references
Front. Oncol.
0 references
4
0 references
Targeting the PI3K/mTOR pathway in pediatric hematologic malignancies (English)
0 references
108-
0 references
